**19. Antibody-fusion constructs**

These are molecules synthesized using recombinant DNA technology. They combine targeting efficiency of IgG and various protein domains. This fusion affects selectivity and PK parameters extensively. Toxic proteins can be used to form immunotoxic compounds such as diphtheria toxin attached to antibodies. Dose-limiting toxicity and immunogenicity are the main challenges in the formation of such complexes. The most successful examples of protein fusion complex are

**89**

**Author details**

Sankha Bhattacharya\* and Kapil Gore

provided the original work is properly cited.

Department of Pharmaceutics School of Pharmacy and Technology Management,

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, India

\*Address all correspondence to: sankhabhatt@gmail.com

*Targeted Cancer Therapy Using Nanoparticles and Antibody Fragments*

nation shows an excellent immune response against the tumor [67].

bioactive proteins attached to the crystallization region of IgG. Amevive and zaltrap are two such complexes approved by USFDA for release in the market. This combi-

**Types of antibody fragments:** Deferent type of antibody fragments are men-

There is no single magic remedy that acts against all of the diseases. Antibodies are ingenious proteins targeted toward specific foreign molecules inside the body. Their therapeutic use involves their ability to disrupt signal transduction, block receptor, which further affects cell growth and cell death. They also can be used to stimulate the immune system so as to destroy any foreign or ingenious harmful materials. IgG's natural structure can be modified to remove problematic residues and add newly modified proteins for the purpose of targeting and immunostimulating. These attachments come with issues like immunogenicity, acquired resistance. But more research in field of antibody engineering is required to address this issue.

*DOI: http://dx.doi.org/10.5772/intechopen.96550*

tioned in **Figure 3**.

**20. Conclusion**

**Figure 3.** *Types of antibody fragments.*

bioactive proteins attached to the crystallization region of IgG. Amevive and zaltrap are two such complexes approved by USFDA for release in the market. This combination shows an excellent immune response against the tumor [67].

**Types of antibody fragments:** Deferent type of antibody fragments are mentioned in **Figure 3**.
